Proteasome inhibition as a new therapeutic concept;Proteasominhibition als neues therapiekonzept

Tumor Diagnostik und Therapie

Volumn 27, Issue 5, 2006, Pages 215-220

  Wäsch, Ralph ^a   Denz, U ^a   Engelhardt, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bortezomib; Cell cycle; Multiple myeloma; Proteasome inhibition; Ubiquitin

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

CANCER; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HUMAN; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PROTEIN DEGRADATION; REVIEW; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

EID: 33751345587     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926986     Document Type: Review

References (33)

1. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005; 6: 79-87
2. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360
3. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502
4. Garban F, Attal M, Michallet M et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474-3480
5. Haas PS, Bauchmüller K, Kühnemund A et al. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. Ann Hematol 2006; 85: 191-193
6. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995; 217: 1070-1077
7. Orlowski RZ, Eswara JR, Lafond-Walker A et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58: 4342-4348
8. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076
9. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-4427
10. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617
11. Jagannath S, Barlogie B, Berenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172
12. Engelhardt M, Muller AM, Maier W et al. Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient. Leukemia 2005; 19: 869-870
13. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498
14. Richardson P, Sonneveld P, Schuster M et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood 2005; 106: 715a
15. Dispenzieri A. Bortezomib for myeloma - much ado about something. N Engl J Med 2005; 352: 2546-2548
16. Jagannath S, Durie BG, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-783
17. Orlowski RZ, Voorhees PM, Garcia RA et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-3065
18. Oakervee HE, Popat R, Curry N et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755-762
19. Wang M, Delasalle K, Giralt S et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005; 106: 231a
20. Richardson P, Schlossman R, Munshi N et al. A phase 1 trial of lenalidomide (REVLIMID®) with bortezomib (VELCADE®) in relapsed and refractory multiple myeloma. Blood 2005; 106: 110a
21. Zangari M, Barlogie B, Burns MJ et al. Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T. Blood 2005; 106: 717a
22. Palumbo A, Ambrosini MT, Pregno P et al. Velcade™ plus melphalan, prednisone, and thalidomide (V-MPT) for advanced multiple myeloma. Blood 2005; 106: 717a
23. Kropff M, Bisping G, Liebisch P et al. Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Blood 2005; 106: 716a
24. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684
25. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675
26. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003; 29 (Suppl 1): 21-31
27. Aghajanian C, Dizon DS, Sabbatini P et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005; 23: 5943-5949
28. Chanan-Khan AA, Richardson PG, Alsina M et al. Phase 1 Clinical Trial of KOS-953 + Bortezomib (BZ) in Relapsed Refractory Multiple Myeloma (MM). Blood 2005; 106: 109a
29. Hideshima T, Bradner JE, Wong J et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005; 102: 8567-8572
30. Chauhan D, Catley L, Li G et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-419
31. Altun M, Galardy PJ, Shringarpure R et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005; 65: 7896-7901
32. Wäsch R, Cross FR. APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit. Nature 2002; 418: 556-562
33. Wäsch R, Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 2005; 24: 1-10